Loading blog post…
A complete guide to coenzyme Q10 (CoQ10/ubiquinone/ubiquinol) in skincare — its role as the electron carrier in the mitochondrial electron transport chain and endogenous antioxidant in cell membranes, why CoQ10 levels in skin decline with age and UV exposure, the Hoppe 1999 study showing CoQ10 reduces UVA-induced collagen degradation, topical vs oral delivery comparison, the reduced form (ubiquinol) vs oxidized form (ubiquinone) in products, and how CoQ10 fits into an antioxidant-focused skincare routine.
· By MedSpot Editorial · 5 min read
Coenzyme Q10 — known as CoQ10, ubiquinone (oxidized form), or ubiquinol (reduced, active form) — is a fat-soluble quinone molecule central to mitochondrial energy production and a significant endogenous antioxidant in skin cell membranes. Its decline with age and UV exposure makes it a logical target for topical supplementation. Here is the complete guide.
CoQ10 is the mobile electron carrier in the mitochondrial inner membrane — it shuttles electrons from NADH (Complex I) and FADH₂ (Complex II) to cytochrome bc1 complex (Complex III) in the electron transport chain. Without adequate CoQ10, ATP synthesis is impaired.
In skin: Keratinocytes in the stratum basale and dermis fibroblasts are metabolically active cells that require efficient ATP production. CoQ10 supports:
In its reduced form (ubiquinol — CoQ10H₂), coenzyme Q10 is the primary lipid-soluble antioxidant in cell membranes, alongside vitamin E. Ubiquinol:
The CoQ10 → Vitamin E connection: The same synergistic recycling relationship seen between vitamin C and vitamin E at the aqueous/lipid interface also exists between ubiquinol and vitamin E at the mitochondrial membrane. CoQ10 operates in a deeper membrane compartment than where vitamin E is oxidized, reducing it back to functional form.
Age: CoQ10 synthesis requires mevalonate pathway activity. Endogenous CoQ10 production peaks in the 20s and declines significantly by age 40–50, with dermal CoQ10 reduced by ~50% by age 80 in some studies. The decline parallels — and may contribute to — reduced fibroblast activity and collagen synthesis.
UV exposure: UVA radiation directly oxidizes ubiquinol to ubiquinone in skin within minutes of exposure. Repeated UV exposure progressively depletes the reduced (active) CoQ10 pool. Studies measuring CoQ10 levels in sun-exposed vs. sun-protected skin of the same individual show significantly lower CoQ10 in photoexposed areas.
Statins: Statins (cholesterol-lowering drugs) inhibit the mevalonate pathway, reducing endogenous CoQ10 synthesis. Patients on statins have measurably lower CoQ10 levels systemically and in skin. This is a specific patient population where CoQ10 supplementation (oral or topical) may have greater benefit.
Hoppe U, Bergemann J, Diembeck W, et al. (1999). Coenzyme Q10, a cutaneous antioxidant and energizer. Biofactors, 9(2–4), 371–378.
This Beiersdorf study (Nivea parent company) demonstrated:
Industry-associated but mechanistically grounded: the MMP-1 inhibition is a documented mechanism by which UV-induced ROS degrades collagen — CoQ10 interrupting the UVA → ROS → MMP-1 cascade is a well-supported anti-aging mechanism.
Subsequent research confirmed that topical CoQ10 at concentrations of 0.3–1% penetrates the stratum corneum into the epidermis and produces measurable reductions in oxidative stress biomarkers in photoexposed skin. The dermis remains a more difficult target due to CoQ10's relatively large size (863 Da).
Ubiquinone (CoQ10): The oxidized form — the standard in most supplements and many skincare products. Must be reduced to ubiquinol to exert antioxidant activity. This reduction occurs in skin through NADH-dependent oxidoreductase enzymes.
Ubiquinol (CoQ10H₂): The reduced, active form — directly antioxidant. Does not require cellular reduction before activity. More expensive to manufacture (less stable); in skincare it may provide faster antioxidant action, though the skin has the enzymatic capacity to reduce ubiquinone.
For topical use: Both forms are used in skincare products. Ubiquinol has a theoretical activity advantage; ubiquinone is more stable in formulation. Most published topical CoQ10 studies used ubiquinone (the cheaper, more stable form) and still showed positive results — suggesting the in-skin reduction is sufficient.
| Route | Reach in Skin | Dose | Notes |
|---|---|---|---|
| Topical 0.3–1% | Epidermis primarily | Applied directly | Direct surface antioxidant; limited dermal penetration |
| Oral 100–300mg/day | Full thickness (via bloodstream) | Systemic | Reaches dermis; benefits cardiovascular co-supplementation |
Oral CoQ10 (100–300mg/day) is better-studied for systemic outcomes and likely provides better dermal coverage. Topical CoQ10 provides direct epidermal antioxidant protection that the oral route cannot specifically target. Combined use is rational for photoaged skin.
AM antioxidant layer: CoQ10 in an antioxidant serum applied before SPF provides epidermal antioxidant protection against UVA-generated ROS. Compatible with vitamin C (complementary mechanisms; CoQ10 works in the lipid membrane compartment, vitamin C in the aqueous).
Combination products: CoQ10 is frequently formulated with vitamin E (its recycling partner), vitamin C, and tocotrienols. Multi-antioxidant formulas exploiting these synergies are more effective than single-antioxidant approaches.
Night creams: CoQ10 appears frequently in anti-aging night creams — at night, no UV challenge but the skin's repair and collagen synthesis processes are active. CoQ10 supports fibroblast energy metabolism for overnight repair.
Oral supplementation: 100–200mg/day with a fat-containing meal (fat-soluble; requires dietary fat for absorption). Particularly relevant for statin users and patients over 50.
Looking for an anti-aging skincare consultation or collagen-stimulating treatment? Browse med spa providers on MedSpot →